Back to Search
MICHAEL SMITH, MD
MD
Student in an Organized Health Care Education/Training Program
NPI: 1275196354IndividualAccepts Medicare
Specialties, Licenses & Credentials
Student in an Organized Health Care Education/Training ProgramPrimary
Student in an Organized Health Care Education/Training Program
Code: 390200000X
Education
OTHER
Class of 2019
Research & Publications (20)
Denosumab in men receiving androgen-deprivation therapy for prostate cancer.
PMID 19671656·N Engl J Med·2009
4-observational
Indirect regulation of presenilins in CREB-mediated transcription.
PMID 19289467·J Biol Chem·2009
7-preclinical
Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study.
PMID 18398147·J Clin Oncol·2008
3-trial
Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome.
PMID 18348297·Cancer·2008
8-other
Treatment-related diabetes and cardiovascular disease in prostate cancer survivors.
PMID 18790986·Ann Oncol·2008
6-review
Gonadotrophin-releasing hormone agonists, diabetes and cardiovascular disease in men with prostate cancer: which metabolic syndrome?
PMID 18454791·BJU Int·2008
8-other
Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer.
PMID 18308111·Urology·2008
8-other
Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study.
PMID 18001802·J Urol·2008
3-trial
Diabetes and mortality in men with locally advanced prostate cancer: RTOG 92-02.
PMID 18779620·J Clin Oncol·2008
2-rct
Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors.
PMID 18765113·Curr Urol Rep·2008
6-review
Androgen deprivation therapy for prostate cancer: new concepts and concerns.
PMID 17940447·Curr Opin Endocrinol Diabetes Obes·2007
6-review
Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancer.
PMID 17200361·Clin Cancer Res·2007
8-other
Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer.
PMID 17826496·Urology·2007
4-observational
Celecoxib versus placebo for men with prostate cancer and a rising serum prostate-specific antigen after radical prostatectomy and/or radiation therapy.
PMID 16782912·J Clin Oncol·2006
2-rct
Treatment-related osteoporosis in men with prostate cancer.
PMID 17062721·Clin Cancer Res·2006
6-review
Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer.
PMID 16406890·J Urol·2006
8-other
Insulin sensitivity during combined androgen blockade for prostate cancer.
PMID 16434464·J Clin Endocrinol Metab·2006
8-other
Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer.
PMID 16258089·J Clin Oncol·2005
8-other
Therapy Insight: osteoporosis during hormone therapy for prostate cancer.
PMID 16474548·Nat Clin Pract Urol·2005
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 800 WASHINGTON ST # 238
BOSTON, MA 02111 - Phone
- (617) 636-7010
Quick Facts
- NPI
- 1275196354
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 7
- Publications
- 20
Are you this provider?
Claim Your Profile